<ol>
    <li> Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributableto
        67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the GlobalBurden
        of Disease Study 2010. <em>Lancet. </em>2012;380:2224-2260.</li>
    <li> Pirie K, Peto R, Reeves GK, et al. The 21st century hazard of smoking and benefits of stopping: aprospective
        study of one million women in the UK. <em>Lancet. </em>2013;381:133-141.</li>
    <li> Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure to cigarette smoke andelectronic
        cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section LeadershipCouncil and
        Early Career Councils of the American College of Cardiology. <em>J Am Coll Cardiol</em>.2015;66:1378-1391.</li>
    <li> Hackshaw A, Morris JK, Boniface S, et al. Low cigarette consumption and risk of coronary heart disease
        andstroke: meta-analysis of 141 cohort studies in 55 study reports. <em>BMJ</em>. 2018;360:j5855.</li>
    <li> Hu Y, Zong G, Liu G, et al. Smoking cessation, weight change, type 2 diabetes, and mortality. <em>N Engl JMed.
        </em>2018;379:623-632. </li>
    <li> Godtfredsen NS, Holst C, Prescott E, et al. Smoking reduction, smoking cessation, and mortality: a
        16-yearfollow-up of 19.372 men and women from The Copenhagen Centre for Prospective Population Studies. <em>Am
            JEpidemiol. </em>2002;156:994-1001. </li>
    <li> Tverdal A, Bjartveit K. Health consequences of reduced dailt cigarette consumption. <em>Tobacco Control.</em>2006;15:472-480.</li>
    <li> Gerber Y, Myers V, Goldbourt U. Smoking reduction at midlife and lifetime mortality risk in men: aprospective
        cohort study. <em>Am J Epidemiol. </em>2012;175:1006-1012. </li>
    <li> Hart C, Gruer L, Bauld L. Does smoking reduction in midlife reduce mortality risk? Results of 2
        long-termprospective cohort studies of men and women in Scotland. <em>Am J Epidemiol. </em>2013;178:770-779.</li>
    <li> Lindson-Hawley N, Hartmann-Boyce J, Fanshawe TR, et al. Interventions to reduce harm from continued
        tobaccouse. <em>Cochrane Database Syst Rev. </em>2016;10:Cd005231. </li>
    <li> Abrams DB, Glasser AM, Pearson JL, et al. Harm minimization and tobacco control: reframing societal viewsof
        nicotine use to rapidly save lives. <em>Annu Rev Public Health. </em>2018;39:193-213. </li>
    <li> Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smokingcessation
        (review). <em>Cochrane Database Sys Rev. </em>2018;5:CD000146.</li>
    <li> Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview
        andnetwork meta-analysis. <em>Cochrane Database Syst Rev. </em>2013;4:CD006103. </li>
    <li> Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. <em>CochraneDatabase
            Syst Rev. </em>2012;4. </li>
    <li> Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. <em>CochraneDatabase
            Syst Rev. </em>2016;5:CD006103</li>
    <li> Gonzales D, Rennard SI, Nides M, et al; for the Varenicline Phase 3 Study Group. Varenicline, analpha4beta2
        nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo forsmoking
        cessation: a randomized controlled trial. <em>JAMA</em>. 2006;296:47-55. </li>
    <li> Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic
        acetylcholinereceptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a
        randomizedcontrolled trial. <em>JAMA</em>. 2006;296:56-63. </li>
    <li> Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled trial of varenicline, a
        selectivealpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation
        in Asiansmokers. <em>Clin Ther.</em> 2007;29:1027-1039. </li>
    <li> Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation: a placebo-controlled, randomized study.<em>Respirology</em>
        2009;14:384-392. </li>
    <li> Bolliger CT, Issa JS, Posadas-Valay R, et al. Effects of varenicline in adult smokers: a
        multinational,24-week, randomized, double-blind, placebo-controlled study. <em>Clin Ther. </em>2011;33:465-477.
    </li>
    <li> Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation inpatients
        with cardiovascular disease: a randomized trial. <em>Circulation. </em>2010; 121:221-229.</li>
    <li> Tashkin DP, Rennard S, Hays JT, et al. Effects of varenicline on smoking cessation in patients with mild
        tomoderate COPD: a randomized controlled trial. <em>Chest.</em> 2011;139:591-599. </li>
    <li> Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with
        stablytreated current or past major depression: a randomized trial. <em>Ann Int Med</em> 2013;159:390-400. </li>
    <li> Rennard S, Hughes J, Cinciripini PM, et al; Flexible Quit Date Study Group. A randomized
        placebo-controlledtrial of varenicline for smoking cessation allowing flexible quit dates. <em>Nic Tob Research</em>2012;14:343-350.</li>
    <li> Gonzales D, Hajek P, Pliamm L, et al. Retreatment with varenicline for smoking cessation in smokers whohave
        previously taken varenicline: a randomized, placebo-controlled trial. <em>Clin Pharm Therap.</em>2014;96:390-396.</li>
    <li> Tonstad S, Tønnesen P, Hajek P, et al; Varenicline Phase 3 Study Group. Effect of maintenancetherapy
        with varenicline on smoking cessation: a randomized controlled trial. <em>JAMA. </em>2006;296:64-71.</li>
    <li> Evins E, Cather C, Pratt SA. Maintenance treatment with varenicline for smoking cessation in patients
        withschizophrenia and bipolar disorder: a randomized, clinical trial. <em>JAMA. </em>2014;311:145-154.</li>
    <li> Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion,and
        nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind,
        randomised,placebo-controlled clinical trial. <em>Lancet. </em>2016;387:2507-2520.</li>
    <li> Barboza JL, Patel R, Patel P, et al. An update on the pharmacotherapeutic interventions for smokingcessation.
        <em>Expert Opin Pharmacother. </em>2016;17:1483-1496.</li>
    <li> Bartsch AL, Härter M, Niedrich J, et al. A systematic literature review of self-reported
        smokingcessation counseling by primary care physicians. <em>PLoS One. </em>2016;11:e0168482.</li>
    <li> Royal College of Physicians. Nicotine without smoke: Tobacco harm reduction. April
        2016.https://www.rcplondon.ac.uk/file/3563/download?token=Mu0K_ZR0. Accessed October 12, 2018.</li>
    <li> McNeill A, Brose LS, Calder R, et al. E-cigarettes: an evidence update. A report commissioned by PublicHealth
        England.
        2015.https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/733022/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf.Accessed
        October 12, 2018.</li>
    <li> McNeill A, Brose LS, Calder R, et al. Evidence review of e-cigarettes and heated tobacco products 2018.
        Areport commissioned by Public Health England.
        2018.https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/684963/Evidence_review_of_e-cigarettes_and_heated_tobacco_products_2018.pdf.Accessed
        October 12, 2018.</li>
    <li> Japan Tobacco Inc. Japanese Domestic Cigarette Sales Results for July 2018. August 17,
        2018.https://www.jt.com/media/news/2018/pdf/20180817_02.pdf. Accessed October 12, 2018. </li>
    <li> Hajek P, Peerbux S, Philips-Waller A, et al. Interest in using varenicline and its effects in people whoboth
        smoke and vape. Poster presented at: Society for Research on Nicotine and Tobacco Europe 18<sup>th</sup>Annual
        Conference; September 6-8, 2018; Munich, Germany. Med-1.</li>
    <li> World Health Organization. <em>WHO Framework Convention on Tobacco Control.</em> Geneva, Switzerland;
        WorldHealth Organization; 2003.</li>
    <li> Gulland A, et al. WHO urges restrictions on e-cigarettes. <em>BMJ </em>2016;355:i5991.</li>
    <li> National Institute for Health Care Excellence. Stop smoking interventions and services. NICE guidelineNG92.
        March 28, 2018. nice.org.uk/guidance/ng92. Accessed October 12, 2018.</li>
    <li> Verbiest M, Brakema E, van der Kleij R, et al. National guidelines for smoking cessation in primary care:
        aliterature review and evidence analysis. <em>NPJ Prim Care Respir Med. </em>2017;27:2</li>
    <li> Canadian Action Network for the Advancement, Dissemination and Adoption of Practice-informed TobaccoTreatment
        (CAN-ADAPTT). Canadian Smoking Cessation Clinical Practice Guideline.
        2011.https://www.peelregion.ca/health/professionals/events/pdf/2013/canadaptt-summary-statements.pdf.
        AccessedOctober 12, 2018. </li>
    <li> Schraufnagel DE, Blasi F, Drummond MB, et al; Forum of International Respiratory Societies.
        Electroniccigarettes. A position statement of the forum of international respiratory societies. <em>Am J Respir
            Crit CareMed. </em>2014;190:611-618. </li>
</ol>